Trevi Therapeutics (TRVI) Retained Earnings (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly Retained Earnings came in at -$190000.0 in Q1 2026, up 99.94% year-on-year from -$95030.4 in Q1 2025, and down 100.04% quarter-over-quarter from $512.8 million in Q4 2025.
Trevi Therapeutics (TRVI) Retained Earnings (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$190000.0 for Q1 2026.
- On a quarterly basis, Retained Earnings rose 99.94% year-over-year to -$190000.0 in Q1 2026; TTM through Mar 2026 was -$190000.0, a 99.94% increase from a year earlier, with the FY2025 full-year figure at $512.8 million, up 840509.84% from the prior year.
- Retained Earnings eased to -$190000.0 in Q1 2026 per TRVI's latest filing, from $512.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $512.8 million in Q4 2025 and bottomed at -$321.5 million in Q3 2025.
- The 5-year median for Retained Earnings is -$135000.0 (2022), against an average of -$7.0 million.
- Biggest YoY gain for Retained Earnings was 840509.84% in 2025; the steepest drop was 368573.81% in 2025.
- Year by year, Retained Earnings stood at -$122000.0 in 2022, then plunged by 195911.48% to -$239.1 million in 2023, then jumped by 100.03% to $61000.0 in 2024, then soared by 840509.84% to $512.8 million in 2025, then tumbled by 100.04% to -$190000.0 in 2026.
- Per Business Quant, the three latest TRVI Retained Earnings figures stand at -$190000.0 (Q1 2026), $512.8 million (Q4 2025), and -$321.5 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Trevi Therapeutics | 2.50 Bn | 2.50 Bn | - | -190,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190,000.00 |
| Dec 31, 2025 | 512.77 Mn |
| Sep 30, 2025 | -321.49 Mn |
| Jun 30, 2025 | -309.69 Mn |
| Mar 31, 2025 | -297.39 Mn |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | -84,000.00 |
| Mar 31, 2024 | 322.37 Mn |
| Dec 31, 2023 | -239.13 Mn |
| Sep 30, 2023 | -231.31 Mn |
| Jun 30, 2023 | -248,000.00 |
| Mar 31, 2023 | 318.23 Mn |
| Dec 31, 2022 | -122,000.00 |
| Sep 30, 2022 | 314.67 Mn |
| Jun 30, 2022 | -135,000.00 |
| Mar 31, 2022 | -188.25 Mn |
| Dec 31, 2021 | -180.92 Mn |
| Sep 30, 2021 | -172.40 Mn |
| Jun 30, 2021 | -165.14 Mn |